Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 1 for:    archus orthopedics
Previous Study | Return to List | Next Study

Total Facet Arthroplasty System®(TFAS®) Clinical Trial

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2009 by Archus Orthopedics, Inc..
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Archus Orthopedics, Inc.
ClinicalTrials.gov Identifier:
NCT00418197
First received: January 2, 2007
Last updated: February 4, 2009
Last verified: February 2009

January 2, 2007
February 4, 2009
August 2005
Not Provided
The primary safety and efficacy evaluation endpoints to determine individual patient success are the Zurich Claudication Questionnaire (ZCQ), neurologic status, solid fusion for the control (spinal fusion) group.
Same as current
Complete list of historical versions of study NCT00418197 on ClinicalTrials.gov Archive Site
Visual Analog Scales (VAS) for Leg and Back pain, SF-36 scores, radiographic measurements.
Same as current
Not Provided
Not Provided
 
Total Facet Arthroplasty System®(TFAS®) Clinical Trial
A Prospective and Randomized Controlled Trial to Evaluate the Safety and Effectiveness of Total Facet Arthroplasty in the Treatment of Degenerative Spinal Stenosis

The Archus Total Facet Arthroplasty System® (TFAS®) is a non-fusion spinal implant indicated for treatment of patients with moderate to severe spinal stenosis. TFAS® replaces the diseased facets following surgical removal. TFAS® offers the surgeon new options for treating spinal stenosis patients, enabling a more comprehensive decompression via complete removal of the facets. TFAS® also offers an alternative to rigid spinal fusion fixation enabling intervertebral motion. The clinical trial is intended to demonstrate restoration of stability and sagittal balance to the spine. TFAS® also eliminates the need for painful bone graft harvest from the patient's hip which may be required with fusion procedures.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Spinal Stenosis
  • Low Back Pain
  • Spondylolisthesis
  • Lumbar Spinal Stenosis
  • Leg Pain
  • Spinal Diseases
Device: Total Facet Arthroplasty System® (TFAS®)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
450
Not Provided
Not Provided

Inclusion Criteria:

  • Degenerative spinal stenosis, central or lateral, at spinal levels L3-L4 or L4-L5
  • Skeletally mature male or female between the ages of 50 and 85 years of age inclusive
  • No greater than Grade I degenerative spondylolisthesis at the index level
  • Persistent leg symptoms,including pain, numbness, burning or tingling for a minimum duration of six months
  • Operative candidates with no more than three levels of degenerative lumbar spinal stenosis requiring decompression
  • Failed to respond to non-operative treatment modalities for a minimum duration of six months

Exclusion Criteria:

  • Male or female less than 50 or greater than 85 years old Grade 2 or higher spondylolisthesis or any retrolisthesis at the index level
  • More than 3 vertebral levels of degenerative spinal stenosis requiring decompression
  • More than 1 vertebral level of degenerative spinal stenosis requiring instrumentation
  • Not available for long term follow-up and interval visits
  • Prior or concurrently planned lumbar fusion or disc replacement at any level of the lumbar spine
  • Two or more previous surgeries to the lumbar spine at the same level to be implanted
  • Is being treated with other devices for the same disorder (e.g. pain control devices)
  • Active systemic infection or infection at the operating site
  • Osteoporosis
  • Known sensitivity to device materials
  • Has an immunosuppressive disorder
  • Has a medical condition that may interfere with clinical evaluations
  • Is obese defined by a patient body mass index greater than 40
  • Has significant scoliosis (Cobb >25°)
  • Is pregnant or planning to become pregnant within the proposed three year investigation
Both
50 Years to 85 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00418197
PR0051
Not Provided
Not Provided
Archus Orthopedics, Inc.
Not Provided
Not Provided
Archus Orthopedics, Inc.
February 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP